New research describing the fundamental biology behind Amplia Therapeutics’ (ASX: ATX) planned Phase 2 clinical trial on pancreatic cancer patients has highlighted the potential benefits of using a focal adhesion kinase (FAK) inhibitor prior to administering standard chemotherapy.
To view media story please click here.
